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Nutrigenetic research examines the effects of inter-individual differences in genotype on responses to nutrients and other
food components, in the context of health and of nutrient requirements. A practical application of nutrigenetics is the use of
personal genetic information to guide recommendations for dietary choices that are more efficacious at the individual or
genetic subgroup level relative to generic dietary advice. Nutrigenetics is unregulated, with no defined standards, beyond
some commercially adopted codes of practice. Only a few official nutrition-related professional bodies have embraced the
subject, and, consequently, there is a lack of educational resources or guidance for implementation of the outcomes of
nutrigenetic research. To avoid misuse and to protect the public, personalised nutrigenetic advice and information should
be based on clear evidence of validity grounded in a careful and defensible interpretation of outcomes from nutrigenetic
research studies. Evidence requirements are clearly stated and assessed within the context of state-of-the-art ‘evidence-based
nutrition’. We have developed and present here a draft framework that can be used to assess the strength of the evidence
for scientific validity of nutrigenetic knowledge and whether ‘actionable’. In addition, we propose that this framework be
used as the basis for developing transparent and scientifically sound advice to the public based on nutrigenetic tests. We
feel that although this area is still in its infancy, minimal guidelines are required. Though these guidelines are based on semi-
quantitative data, they should stimulate debate on their utility. This framework will be revised biennially, as knowledge on
the subject increases.
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Personalised nutrition (PN), based on an individual’s geno-
type, is not new. Individuals with rare genetic disorders such
as phenylketonuria, galactosemia and hereditary fructose
intolerance [1–3]) as well as more common disorders (e.g.
lactose intolerance, coeliac disease [4, 5]) tailor food intake
to bypass the metabolic deficiency. In each case, specific
dietary recommendations have been defined, validated and
are in use clinically. A key question for the clinical and nutri-
tion community is whether matching nutrient intake and
physical activity to individual gene variants, that usually pro-
duce weaker metabolic effects compared to those mentioned
above, would have noticeable impacts on health status.
Many sectors of modern society increasingly focus on
personalising services or products to enable individuals
to control more aspects of their lives. Public interest in
personalised health has spurred growth in nutrigenetic
testing services not only for disease susceptibilities but,
especially, for optimising nutrition. Genetic testing is a
largely unregulated market with many unsupported
claims and inadequate explanations of the results and
implications [6–11]. It is important to be aware that the
effects of common variants will be mostly small in the
overall phenotype and which will depend on several
variants, gene-gene and gene-protein interactions. A
common weakness in the commercial area (for all of
nutrition) is to provide simple “answers” to a complex
question. Hence, the aim of this paper is to provide a
draft framework for assessing the validity of genetic
information for the development of precise personalised
dietary advice that does not go beyond the evidence.
The general objective of PN is to maintain or improve
health by using genetic, phenotypic, clinical, dietary and
other information to provide more precise and more
efficacious personalised healthy eating advice and to
motivate appropriate dietary changes. For example,
about 15 years ago, it was proposed that:
“With the identification of polymorphisms, or
common mutations, in vitamin metabolism, large
percentages of the population may have higher
requirements for specific vitamins ([12]).”
Research since then has resulted in significant progress
and has identified some well-defined gene × diet interac-
tions supporting the concept that diets tailored to the
individual’s genotype might result in long-term health bene-
fits [9, 13, 14]. Personalised advice should be more precise
and more efficacious than generic advice. To facilitate
acceptance by the public and other stakeholders, it is
important that the development of genotype-dependent
advice is based on sound evidence. The debate about direct
to consumer (DTC) sales of genetic testing and the regula-
tion of this market ([10, 15–18]), are beyond the scope ofthis article. DTC is a reality that makes it important that
information about links between genetic variants, nutrition,
and health and reliable interpretation of that information
are accessible to all stakeholders including healthcare
professionals, regulators, companies and the public.
The development of the framework described herein is
part of a larger project within the EU FP7 project
Food4Me (www.food4me.org), which was initiated to
examine several aspects of PN including business models,
market readiness, ethics and public perceptions, and to
perform a Europe-wide proof of principle intervention
study on the effectiveness of PN approaches [19, 20]. A
specific goal within the Food4Me project was the creation
of a publicly available resource listing gene × diet interac-
tions [21]. PN may contribute to improved eating patterns
and help reduce the burden of many common health
problems including obesity, age-related diseases such as
type 2 diabetes (T2D), cardiovascular disease (CVD),
dementia, musculoskeletal problems and some cancers
[22]. Therefore, when validated, scientific evidence of
potential benefit should be communicated to healthcare
professionals and to the public in an objective and trans-
parent manner [9]. In this paper, we propose a set of
minimum standards of evidence required for the evalu-
ation of the scientific validity of genotype-based persona-
lised dietary advice.
Review
The context of nutrigenetics
PN should be evaluated in the context of conventional
“healthy eating” advice, which forms the basis of public
health recommendations aimed at guiding diet and lifestyle
habits in populations. These include dietary reference
values (DRVs) which aim to promote health by optimising
nutrient intake (including setting upper safe limits for nu-
trients to minimise harm from over-consumption) and to
prevent or delay non-communicable diseases ([23, 24, 25]).
Although some DRVs are group-specific i.e. they take
account of sex, age and physiological state (pregnancy or
lactation), they are in essence a “one-size fits all” approach
within each group. Consideration of inter-individual
variation in requirements is included statistically through
setting DRVs. They are designed to meet the needs of
97.5% of the population which means that while the DRV
will be greater than the needs of most individuals in the
population, the needs of some individuals may not be
covered by the established group-based reference values.
Recent efforts have refined this approach to include
subgroups [25], and a strategy for such refinement was
proposed by the EU funded “network of excellence”,
EURRECA––Harmonising nutrient recommendations
across Europe with special focus on vulnerable groups and
consumer understanding ([26, 27]). However, with very few
exceptions (e.g. folate), specific methods for evaluation and
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general dietary advice are lacking.
Genotype is one class of information [28, 29] that can be
used to personalise dietary advice and should be used in
combination with other relevant information (e.g. sex, age,
anthropometrics, health status, family history or dietary
preferences) and never in isolation. In this regard, the
appropriate level of evidence for nutrigenetic-based advice
is similar to that used in development of conventional
nutritional guidelines. However, despite being based on a
similar scientific evidence base, such guidelines often differ
between countries. This is because, in formulating nutri-
tional guidelines, expert committees make decisions based
on the best evidence available, while acknowledging
knowledge gaps, and taking into account country-specific
issues [25].Methodology
A ‘Global Nutrigenetics Knowledge Network’ was estab-
lished (starting in the Food4Me EU project), involving
experts in different areas of PN, to collate all relevant infor-
mation on genetic variations involved in the nutrient-health
relationships and deliver guidelines for the evaluation of
evidence for diet-gene interactions. The aims are:
1. To provide a draft framework for assessing the
evidence for scientific validity of:
a. Personalised dietary advice based on a specific
gene variant
b. Personalised dietary advice based on a specific
gene variant that is already available in
commercial nutrigenetic tests
2. To create a series of Nutritional GeneCards––based
on this draft framework––each of which assesses
the evidence for a particular gene-diet/lifestyle
interaction.
The Global Nutrigenetics Knowledge Network reviewed
guidelines for genetics, medical genetic tests and nutritional
recommendations (Evaluation of Genomic Applications in
Practice and Prevention (EGAPP), Strengthening the
Reporting of Genetic Association Studies (STREGA),
Grading of Recommendations Assessment, Development
and Evaluation (GRADE), European Food Safety Authority
(EFSA) [30–34]) and concluded that these did not fully
cover the needs for assessing the evidence for genetics-
based personalised dietary advice. EGAPP assesses the
clinical utility of a gene, or genes, in conjunction with their
variants as predictors of disease, and EFSA assesses the
evidence for the potential nutritional or health benefits of
specific foods or food components. However, none of these
guidelines addresses the evidence from studies that investi-
gate the combined effect of genotype plus diet on healthoutcomes, which is essential for establishing evidence-
based nutrigenetic advice.
The Clinical Pharmacogenetics Implementation
Consortium (CPIC) guidelines for pharmacogenetics
(gene-drug interactions) have some relevance to nutri-
genetics, and we agree with their aim ‘to provide
guidance to clinicians as to how available genetic test
results should be interpreted to ultimately improve
drug therapy, rather than to provide guidance as to
whether a genetic test should or should not be ordered’.
[35, 36] The CPIC evidence assessment is simpler, relative
to nutrigenetics, because (usually) the drug is metabolised
by the gene product and has effects over a short time. On
the other hand, the risk/benefits equation is such that the
evidence would need a higher standard than that applied
to nutrition and nutrigenetics.
The ACCE model (Analytical and Clinical Validity,
Clinical Utility and Ethics, [37]) for evaluating genetic
tests in general was considered an appropriate starting
point for genotypic assessment but, in the present
context, required modification to recognise that geno-
typic information will be used in developing PN advice
for the public rather than for medical diagnostics.
According to ACCE, a medical genetic test should fulfil
requirements regarding:
i. Analytical validity––a measure of the accuracy of
the genotyping.
ii. Scientific validity––concerns the strength of the
evidence linking a genetic variant with a specific
outcome
iii. Clinical utility––the measure of the likelihood that
the recommended advice or therapy will lead to a
beneficial outcome beyond the current state of the
art.
iv. Ethical, legal and social implications that may arise
in the context of using the test.
The regulation for analytical validity is relatively
straightforward, and many countries have laboratory
accreditation procedures that cover accuracy and repro-
ducibility [38]. Ethical and legal aspects of nutrigenetics
are discussed elsewhere [7, 8]. Clinical utility has strict
criteria in the medical sense, demanding strong evidence
that a given therapy ‘will lead to an improved health
outcome’ [39]. A likelihood ratio (LR) of six or greater is
usually considered to be indicative of clinical utility [40].
LR is the likelihood that a given test result would be
expected in a patient with the target disorder compared
to the likelihood that that same result would be expected
in a patient without the target disorder [41]. It could, in
principle, be useful to measure the likelihood ratio of the
efficacy of nutrigenetic advice relative to generic advice,
and a rank of LRs might then be used as an objective
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is that defining an ‘improved health outcome’ due to
nutrigenetic advice in a generally healthy person is very
hard to do. Therefore, the present document will
concentrate on the development of a draft framework
for the assessment of scientific validity, and it will not
directly address claims about clinical utility or ‘personal
benefit’, see Table 1.Proposed framework for scientific evidence
assessment
The components relevant to this assessment are sum-
marised in Table 2. This draft framework will be used in
‘nutrition gene cards’ that assess the evidence supporting
specific gene × diet interactions and its relation to a
specific health outcome (see below). In the framework, we
implement components used in systematic reviews [42],
including the development of the search strategy and the
assessment of the study quality.
Scientific validity may be graded as (the percentages
are based on the Guidance on Uncertainty in EFSA
Scientific Assessment [43]):Probability term Subjective probability range (%)A. Convincing > 90B. Probable 66–90C. Possible 33–66D. Insufficient < 33“Convincing” should be based on several (at least three)
strong studies with high subject numbers, showing the
relation and/or mechanistic knowledge, “probable” based
on several studies showing the relation and/or some
mechanistic understanding and “possible” based on a few
studies showing the relation. See below in the text for a
fuller explanation.
Scientific validation determines the strength of the
evidence for an interaction between a specific genetic
marker or set of markers and a dietary component or
pattern on a health outcome of interest (such as disease
or risk factors for disease). The scientific validity criteria
for genetic-based dietary advice within this proposed
framework include (i) study design and quality and (ii)
biological mechanism including the nature of the genetic
variant(s) and biological plausibility, as discussed below.
The probability term is the overall judgement of the
evidence provided, and in this sense ‘it is possible for an
evidentiary conclusion based on many papers, each of
which may be relatively weak, to be graded as ‘moderate’
[probable] or even ‘strong’ [convincing], if there are
multiple small case reports or studies that are all
supportive with no contradictory studies’ [36].1. Study design and quality
All studies reporting on genetic interactions should
adhere to the STREGA guidelines [33]. STREGA was
developed with aim of improving the transparency of
reporting involving ‘population stratification, genotyping
errors, modelling haplotype variation, Hardy-Weinberg
equilibrium, replication, selection of participants, ration-
ale for choice of genes and variants, treatment effects in
studying quantitative traits, statistical methods, related-
ness, reporting of descriptive and outcome data, and the
volume of data issues that are important to consider in
genetic association studies’ [33].
Only studies that include STREGA guidelines should
be considered when assessing a gene-diet interaction. In
addition to the STREGA guidelines, the intake of the
dietary component of interest should be reported quan-
titatively; for the description on the quantification of diet
intake, see [44].
2. Biological plausibility
‘a gene–environment interaction will only be
accepted if it can be reproduced in two or more
studies and also seems plausible at the biological
level.’ [45]
Biological plausibility is a judgement based on the
collected evidence of a gene × diet interaction on a
phenotype. For example, smoking introduces
carcinogens into the body, which could cause DNA
damage, increased mutational events, and consequently
increasing risk of cancer [46]. Thus, a validated gene ×
nutrition interaction such as GSTM1 × cruciferous
vegetable consumption leading to reduction of DNA
damage ([47, 48]) is consistent with an association
between GSTM1 × cruciferous and reduced cancer
risk ([49]).
Gene × diet interactions, the scientific underpinning
of this paper, are defined here as the particular
physiological response to a dietary component which
occurs only––or is more pronounced––in persons
with a specific version of a gene (or genes). For
example, a certain genotype may be associated with
increased concentrations of LDL cholesterol and
increased risk of cardiovascular complications, but
only in the case of long-term, higher-than-average
saturated fat consumption [28, 50]. Evidence of this
type of interaction may be used to develop an appro-
priate dietary recommendation (e.g. consuming lower
than average intake of saturated fats) which may re-
duce or eliminate the potential negative consequences
associated with the specific genotype and may be tar-
geted to specific groups of people.
Table 1 Why clinical utility is not part of this framework
This framework stops at the assessment of scientific validity. The recommendations provide clear and sufficient detail so that any opinion on health
(or clinical) utility can be derived by the user (including the individual, dietician/nutritionist/medical doctor, companies and claim regulation bodies).
Clinical utility is the measure of the likelihood that the recommended therapy or intervention will lead to a beneficial outcome. Clinical utility is the
most controversial aspect: it is often difficult to define and must take into consideration many factors including positive or negative psychological or
motivational effects on the end user [81]. Others contend that clinical utility can only be thoroughly established through randomised clinical trials
(RCT), but these are challenging for the personal genetics environment, includes diet, lifestyle and behavioural changes and has small cumulative
effects over decades (see [82, 83] for an example of the current debate). A further problem is the precise definition of a clinical benefit. A gene-diet
interaction may not be associated directly with disease risk, such as cardiovascular disease, but with intermediate phenotypes, e.g. lipid levels,
hypertension and homocysteine, which are independent risk factors for disease. Some commentators require that clinical utility is demonstrated as a
reduction in disease incidence. The majority view accepts that lowering of intermediate risk factors is acceptable (as is the case for phytosterols and
their cholesterol lowering properties [50, 84]).
RCTs
In personalised nutrition research, RCTs with disease incidence as the endpoint are not practically feasible as they will require long-lasting nutritional
changes, making compliance difficult and very expensive, at least in terms of primary prevention in healthy people––apart from any ethical problems.
RCTs that address disease incidence reduction in middle-aged or elderly high-risk subjects, secondary prevention in individuals with disease and/or
on effects on intermediate biomarkers or risk factors can be useful, but care is required in drawing conclusions. RCTs in nutrition and genetics are
often complex, difficult to design and challenging to conduct in a reasonable time frame. Some examples given below illustrate this and may be
helpful when interpreting RCT data for personalised diet and lifestyle evidence advice.
Primary prevention in high-risk groups
Genetics × diet × T2DM (type 2 diabetes mellitus)––The T allele of the TCF7L2 rs7903146SNP has been associated repeatedly with an increased risk of
T2DM (2-fold in homozygotes [85]). Compared with non-risk allele carriers, individuals who carry the risk allele and who are at high risk
phenotypically (glucose intolerance, pre-diabetes diagnosis) require a longer lasting and a more intense dietary and lifestyle recommendation to
divert the trajectory from disease over a period of 12 months and to maintain health gains over a 4-year period [86]. Although useful, these findings
have been obtained in clinical trials of unhealthy people, who typically were older. Thus, to be precise, it does not demonstrate, and cannot be used
to claim, that specific dietary modifications in younger, healthier people will prevent the development of glucose intolerance or T2D in those
carrying the risk allele. However, this evidence of gene × diet interactions in pre-diabetics is consistent with the evidence from other types of studies
in healthy subjects (epidemiological, cohort, effects on biomarkers) and can provide supporting evidence, but not conclusive evidence, that specific
dietary guidelines would be appropriate for healthy carriers of this TCF7L2 risk allele. This example shows how difficult it is to validate a gene-diet
interaction but suggests that adjusting the environment will improve the individuals’ health.
The same TCF7L2 genetic variant was assessed in the recently published study from the PREDIMED project [14], a large randomised trial in 7018 high-
cardiovascular-risk individuals comparing two Mediterranean (Med) diets and a control diet. TCF7L2 TT homozygotes at SNP rs7903146 had higher
blood glucose levels, total cholesterol, LDL cholesterol and triglycerides but only when adherence to the Med diet was low. Furthermore, incidence
of stroke was almost three times higher in TT homozygotes as in the control group, but this increased risk was completely dissolved in the Med diet
group (Hazard Ratio, HR = 0.96). Thus, compared to the control diet, both Med diets were effective at reducing both risk biomarkers and disease
incidence itself in a genotype specific manner. While this is a strong endorsement of the Mediterranean diet, it is also relevant that the age range
was 55 to 80 years. This RCT supports the epidemiological evidence for health benefits of the Med diets for older persons, and those at increased risk
of CVD, and can only suggest such benefits for other age groups who carry the TCF7L2 TT genotype at rs7903146.
Secondary prevention in subjects with pathology
MTHFR × folate × homocysteine on CVD risk––results of several large homocysteine-lowering clinical trials have been published over the last decade,
and none reported any benefit in prevention of secondary CVD by folate supplementation. These results have been used widely to declare that there
is no evidence that elevated plasma homocysteine levels are relevant for CVD and that there is no benefit in homocysteine-lowering in primary
prevention [87–89]. However, these were all short-term trials in older people already suffering from (mainly) CVD and taking several medications,
where incidence of further cardiovascular events was measured. None of the trials were performed in healthy people. Thus, the conclusion from
these studies states that over the trial periods there was no apparent benefit in lowering homocysteine in ill people, i.e. as in secondary prevention.
However, still lowering homocysteine by using folate may reduce risks of CVD in healthy people with high risk [53, 90, 91]. For instance, the China
Stroke Primary Prevention Trial [13, 92], reported on a total of 20,702 adults with hypertension without history of stroke or myocardial infarction who
participated in the study. That study compared a single-pill combination containing 10 mg of enalapril and 0.8 mg of folic acid with a tablet
containing 10 mg of enalapril only. Among adults with hypertension, the combined use of enalapril and folic acid, compared with enalapril alone,
significantly reduced the risk of first stroke (HR = 0.79). Analysis of the MTHFR 677 genotype showed further that the TT genotype had the largest risk
reduction in the highest folate quartile (HR = 0.24), suggesting that individuals with the TT genotype may have a greater folate requirement.
MTHFR × riboflavin × hypertension––several RCTs have demonstrated that riboflavin supplementation contributes to blood pressure-lowering
specifically in hypertensive carriers of the 677T allele [52, 93–95]. The trials do not prove primary prevention (i.e. they do not demonstrate that
increasing riboflavin in 677T normotensives prevents development of hypertension), and they do not prove the ultimate health benefit of riboflavin
to reduce incidence of heart disease. However, reducing blood pressure is considered to be a health benefit in itself, and although the results cannot
be used to establish a genotype specific role of riboflavin in primary prevention of hypertension, they can be used to support other types of studies.
Overall, outcomes of RCTs can be useful for nutrition/lifestyle advice, but they need to be interpreted with care. Furthermore, it must be accepted
that conducting an RCT in young healthy people with the aim of investigating the effect of nutrition on actual reduction of disease incidence over the
long term is not feasible either ethically, economically or scientifically (see also [96] for discussion). On the other hand, the use of RCTs to study the
effects on biomarkers that quantify health (i.e. not simple risk markers of impending disease) is a promising new approach [97].
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We identify three broad types of gene × diet interactions:
direct, intermediate and complex. A ‘direct’ interaction is a mechanistic interaction
between the genetic variant and the dietary
component on the health biomarker. This type of
interactions is most similar to metabolism of a drug
Table 2 Framework for stepwise assessment of the evidence
relating to gene × diet interactions
Scientific validity assessment criteria
Study quality rating (A, B, C, D):
* Interventional or observational design
* Prospective and retrospective approach
* Randomised, placebo controlled and blinded
* Study power (high subject number with ‘effect’ allele)
* Effect magnitude
* P values, false discover rate (FDR) and multiple testing
* Replication study in different populations and meta-analysis
Type of gene × diet Interaction:
* Direct phenotype
* Intermediate phenotype
* Indirect phenotype
Nature of the genetic variant
* Causal
* In LD with functional variant
* Associated but unknown function
Biological plausibility
* Rated as high/medium/low/unknown
Scientific validity score for gene × diet interaction
* Convincing
* Probable
* Possible
* Not demonstrated
*P values must be at least .05 to be significant. The P value must remain
within .05 after correcting for multiple testing, e.g. Bonferroni
aThe ‘effect magnitude’ required depends on the type of study. For example,
the effect of folate on high homocysteine in carriers of the effect allele in
MTHFR should be a return to normal within a few weeks of starting the
intervention. The magnitude of reduction of blood pressure would be
acceptable for as little as 1 mmHg, and any risk reduction, however small, for
cardiovascular disease would be adequate
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metabolises the drug.
 An intermediate interaction is a mechanistic
interaction between the genetic variant and the
dietary component on the health biomarker, but
other processes also affect the level of the
biomarker.
 An indirect interaction is the case where a
mechanistic interaction between the genetic variant
and the dietary component on a health biomarker,
including disease, is affected to some extent by the
gene × diet interaction but is also influenced by
many other, possibly unknown processes, and it may
take years for symptoms to manifest. This type of
interaction may not be fully explained
physiologically or may be only demonstrated
statistically.
A well-researched example is the case of supplementation
with folate (substrate) and/or riboflavin (cofactor) in
persons who are carriers or non-carriers of the methylene-
tetrahydrofolate reductase (MTHFR) C677T polymorphism
(rs1801133) where ‘T’ is the allele associated with reduced
enzymatic activity. Examples with the folate-related enzyme
MTHFR are as follows: Direct: e.g.MTHFR × folate→ levels of homocysteine [51]
 Intermediate: e.g. MTHFR × riboflavin → blood
pressure [52]
 Indirect: e.g.MTHFR × folate /riboflavin→ cardiovascular
disease [53](ii) Nature of genetic variant
This draft framework considers three major classes of
genetic variants, with differing strengths of evidence.
a) The genetic variant has a demonstrated causal effect
on the function of the gene product, e.g., on enzyme
activity or protein abundance, which provides a
biologically plausible explanation for the gene-diet
interaction.
b) The genotyped variant may not itself affect the
protein of interest but it may be in linkage
disequilibrium (LD) with another relevant functional
variant––one SNP is said to ‘tag’ the other [54, 55].
Evidence would be required to validate both the LD
score and the putative gene × diet interaction. In
addition, the results also would be applicable only to
the population(s) in which high LD has been
established.
c) The effect of the SNP on function of the gene product
is unknown and is based only on a statistical
association for the gene × diet effect [54, 55].
Examples of these three types of genetic variants are:
– Causative: SNP rs1801133 (TT) reduces the activity
of the MTHFR enzyme [56]
– In LD with known causative variant: the SNP rs4341,
which is in LD with an InDel variant (rs4646994) in
the same gene, ACE, that affects the plasma
angiotensin converting enzyme (ACE) levels ([57, 58])
– Unknown: e.g. rs7903146 (CT and TT) intron SNP
in the TCF7L2 gene is linked to type 2 diabetes risk.
An interaction with carbohydrate and diet has been
demonstrated, but the effect of this polymorphism,
if any, on function of the corresponding gene
product has not been characterised. This SNP may
be in LD with a functional SNP or has an as yet
uncharacterised function ([59, 60]).Scientific validity assessment of a putative gene × diet
interaction
Assessing the validity of a putative gene × diet
interaction is generally complex, and as knowledge
deepens in the area of nutrigenetics, assessment of its
validity will develop. We propose a pragmatic way to
assess the validity by relying initially on semi-quantitative
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numbers used below to assess the validity should be con-
sidered an arbitrary but coherent guideline based on sug-
gested power calculations, and precision of measurements
of diet exposure and outcome [45, 61, 62], plus experience
based on successfully repeated gene × diet studies pub-
lished to date.
The assessment should explicitly specify for which
subgroup (e.g. sex, ancestral background and other
relevant subgroups) the evidence is collected.
Convincing
– Two independent studies that have shown the
relationship between the gene-diet interaction and
the specific health outcome. Together those studies
should include at least 100 subjects carrying the ef-
fect allele (i.e. the presumed functional variant or in
LD with the functional variant) for intervention
studies and at least 500 subjects for observational
studies. Specifically, if the frequency of the effect
allele is 10% that means that a total of at least 1000
and 5000 subjects for intervention and observational
studies, respectively.
– Biological mechanism fully understood or largely
explained.
– Biological mechanism partly explained and having
one correlative study that at least includes 50
(intervention) or 250 (observational) subjects
carrying the effect allele.
Probable
– Two independent studies that have shown the
correlation between the gene-diet and health
outcome (together < 100 (intervention) or 500
(observational) subjects carrying the effect allele)
– One study that has shown the correlation between
the gene-diet and health outcome including at least
100 (intervention) or 500 (observational) subjects
carrying the effect allele.
– Biological mechanism partly explained and having
one small correlative study (< 50 (intervention) or
250 (observational) subjects carrying the effect
allele)
Possible
– One study has shown the correlation between the
gene-diet and health outcome (< 100 (intervention) or
500 (observational) subjects carrying the effect allele)
– Biological mechanism partly explained and having one
small correlative study (< 50 (intervention) or 250
(observational) subjects carrying the effect allele)Not demonstrated
– Any other studies, excluding the abovementioned studies
Based on the factors described above, an overall
assessment of all evidence can be made to arrive at a
combined score on the scientific validity, and our degree
of confidence in that assessment, of the gene × diet
interaction being predictive of the outcome of interest.
Some examples include:
 Convincing––very high confidence. MTHFR and
homocysteine concentrations which are influenced
by dietary folate: a large numbers of studies
including randomised trials, very consistent results,
direct effect of the genetic variation on enzyme
activity, and high biological plausibility [63, 64].
 Probable––high confidence. SOD2 × antioxidants
and prostate and breast cancer risk have been
demonstrated consistently in gene × diets studies.
Some large studies show a reduction in cancer risk
when antioxidant intake is high. The biological
plausibility is high, but all available evidence comes
from prospective or retrospective observation trials
and not randomised trials [65–67].
 Possible––BCMO1 × carotenoid and retinal levels.
The BCMO1 gene product is an enzyme that
converts β-carotene to vitamin A (retinal). Certain
BCMO1 alleles are associated with higher plasma
β-carotene levels, and such allele variants may re-
sult in lower enzyme activity. However, there is
no clear demonstration on the effect of dietary
advice [68, 69].
 Not demonstrated. FADS2 × breastfeeding and IQ––
three published studies, with three conflicting results:○ In 3269 children, in two cohorts (Britain and
New Zealand), an increase in IQ but only in
breastfed infants who were carriers of the C-allele
for the FADS2 rs174575 SNP which is the major al-
lele intronic tag SNP associated with higher docosa-
hexaenoic acid (DHA) [70].
○ Second study examined 5934 British children––
breastfed children with the GG genotype were
actually associated with higher IQ [71].
○ Third study of 1431 Australian children––there
were no differences in IQ either for breastfeeding or
genotype at the FADS2 rs174575 SNP [72].
Conclusion
We have developed a draft framework of criteria
allowing for the assessment of the quality of the
evidence for PN advice based on individual gene
variants. This framework is intended to establish the
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and to determine the likelihood that the predicted
outcomes will be consistent and reproducible. The
fundamental requirement of a nutrigenetic test, as with
any health-related test, is that the results should clearly
indicate a diet-related recommendation that is beneficial
in relation to a concrete aspect of health or perform-
ance. Any such advice should fulfil all requirements set
out in the framework described here. We have not ad-
dressed the ethical aspects of nutrigenetic testing and
whether professional pre- and post-test counselling is re-
quired because this has been addressed and discussed
elsewhere ([8, 11, 15–18]). The framework described
here is limited to evidence of validity, without which ad-
vice should not be given.
The rapidly developing commercial environment, in
conjunction with the interest of public health bodies in
PN, has created a strong need for formal assessments of
the evidence. A large number of gene × diet interactions
which might affect phenotypes pertinent to commonly
occurring diseases have been reported and this number
will increase as data become available from genome-wide
GxE (Gene–environment interaction) studies ([73, 74]).
Furthermore, it is likely that only a proportion of these
reported gene × diet interactions currently could be
judged as valid by the criteria described here and therefore
have a potential benefit in PN.
The nutrigenetics research community organised in the
‘global personalised nutrigenetics knowledge network’ can
contribute to the translation of the accumulating knowledge
into practice by using these proposed guidelines. Regular
reviews (e.g. on a bi-annual basis) of current knowledge of
the most studied polymorphisms may generate additional,
scientifically valid associations and hence provide recom-
mendations about which polymorphisms may inform
genotype-based dietary advice. We will also include reviews
of genetic variants that do not meet these standards. The
practical output for this exercise will be the publication of
nutrient-gene cards in this journal Table 3.Table 3 Application of the framework
This framework described here can be used by dietitians, nutritionists, doctor
of gene(s)-diet interactions. As such, nutrigenetics may develop to be part of
tools should be the basis for dietary advice aimed not only to reduce the ris
health.
Nutrition gene cards
This framework can be used to assess the specific relation between a gene (
Nutrigenetics Knowledge Network also developed the concept of a nutrition
assessing a specific gene-diet interaction. These short publications should inc
The nutrition gene cards should adhere to some basic rules:
1. Studies should be identified in a systematic way, and studies t
consideration.
2. The nutrition gene card should be peer reviewed.
3. All guidelines should be publicly available as an online educat
4. All researchers are invited to contribute to the nutrition gene
Presumably, the lessons learned by writing these nutrition gene cards will shAdoption of nutrigenetics and genetic testing has been
slow in the healthcare system, and we hope that these
guidelines accelerate informative genetic testing for
education and practice. In a recent survey of 373
Canadian registered dietitians, 76% responded that they
do not have sufficient knowledge of nutrigenetics. In
spite of this, the majority stated ‘that genetic testing and
their results have poor accuracy, and that there is a lack
of scientific evidence’ [75]. These contradictory
responses suggest that there is a lack of impartial
objective material available for educating dietitians,
nutritionists and other healthcare professionals ([75]).
However, the American Dietetic Association recently has
published a position paper on nutritional genomics [76].
One important part of that paper interprets nutrigenetics
differently by stating that ‘The practical application of
nutritional genomics for complex chronic disease is an
emerging science and the use of nutrigenetic testing to
provide dietary advice is not ready for routine dietetics
practice as most chronic diseases, such as CVD, diabetes,
and cancer are multigenetic and multifactorial and therefore
genetic mutations are only partially predictive of disease risk’.
We, however, state that the primary goal of nutrigenetics in
the context of this paper is not to predict risk but to develop
genotype-based (one or more gene) dietary advice supple-
menting the standard guidelines for everyday use in the
framework of a health-promoting nutrition.
A genetic test for disease risk prediction would require
different levels of evidence since disease risk predictions
require the contribution of many SNPs. Determining
risks relies on SNPs identified from genome-wide associ-
ation studies (GWAS), many of which are in introns or
gene deserts and have unknown functions. Since all
GWAS and most nutrigenetic testing is based on (study)
population averages, converting population attributable
risk to personal risk is not possible [77]. A risk predic-
tion could involve gene × diet interactions (i.e. nutrige-
netics), but nutrigenetics would not be the primary
source of the risk prediction. For example, MyGeneRanks and genetic counsellors (and customers too) to judge the soundness
standard of care. Ultimately, the use of evidence-based nutrigenetic
k of disease but also as a tool to optimise diet to promote long-term
genes) and nutrient for publication. For this purpose, the Global
gene card, which is a short publication using this framework and
lude all the aspects of Table 2.
hat contain proven statistical flaws will be explicitly removed from
ional resource.
card––either to update current cards or to propose new gene-diet cards.
arpen the framework as described in this paper.
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unknown function, in a genetic risk score (GRS) to pre-
dict coronary artery disease risk. In a second part of the
test, it could be useful to use nutrigenetics (using SNPs
and other variants, like InDels) to help with improving
diet, which in turn can reduce the actual risk compared
to the GRS risk value [78].
In the commercial environment, the field of personal
genetics and nutrigenetics are under increasing scrutiny
from regulators. For example, the US Food and Drug
Administration (FDA) and the Federal Trade
Commission (FTC) limited the scope of direct to
consumer products and services ([79]). Many companies
would likely prefer to commercialise reputable, useful
products and services, but the absence of clear
regulations or guidelines mitigates against such
developments. The lack of educational resources and the
variable quality of tests currently on the market limits
the ability to translate research to utility and reinforces
the need for a framework for assessing validity of gene ×
diet interactions. We have studied and incorporated
recommendations and guidelines from expert groups in
medical genetics and other types of medical tests (e.g.
EGAPP and GRADE [30–32]), with some modification for
the specific and different circumstances and requirements of
nutrition.
Our approach has some limitations and strengths. One
limitation is the general heterogeneity and mixed quality
of studies combining both genetic and nutritional
analysis, often making it difficult to compare apparently
similar studies analysing the same genetic variants and
dietary components. Nutrition research in general is
prone to inconsistency because of the high complexity
and the subtle effects of nutrition on long-term health,
the difficulties in accurate dietary assessment, food-food
or nutrient-nutrient interactions, environmental context
which can alter nutrient hosts interactions and compli-
ance to a specific diet. These same issues also restrict
the use of findings from meta-analysis. Inevitably, any
assessment of nutrition and nutrigenetics can be only
semi-quantitative at best. We consider that our approach
has the benefit of creating a formal and generic model
for the assessment of such evidence and will guide more
focussed debates on specific points, which may be
judged in different ways. Moreover, the framework and
associated resources will allow stakeholders such as
dieticians, nutritionists and genetic counsellors to im-
prove their knowledge of nutrigenetics and at the same
time will provide a resource to assess the various tests
that are offered. This framework may encourage a
greater standardisation of research protocols, supporting
other initiatives such as PhenX [80], as well as the
reporting of novel and replicated gene-environment
interactions in other populations.Abbreviations
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